Abstract:Background The aim of this study was to evaluate the PSA response rate, biochemical relapse-free survival, and toxicity in bone oligometastatic prostate cancer patients who had undergone definitive intensity modulated radiotherapy (IMRT) for both primary tumor and all metastatic lesions. Methods From 10/2011 to 9/2015, 22 prostate cancer patients with bone oligometastases (no more than 5 metastatic lesions) were treated. Metastatic lesions were documented by positive bone scan or CT scan or MRI. All patients received IMRT, 40-76Gyin10-38fractions(mediandose:60Gy)tometastaticlesions,45-46Gytothe wholepelvis(for14patients,63.6%)and72-76Gytotheprostateandseminalvesicles. All patients received MAB using a LHRH agonist or orchiectomy together with an oral anti-androgen before and during RT. After RT, all patients received continuous ADT except one due to cardiovascular disease. Survival was calculated using the Kaplan- Meier method. Results A total of 49 bone metastatic lesions were identified in these 22 patients. The mediannumberofmetastaticlesionsperpatientwas2(range1-5).29(59.1%)lesions werelocalizedinthepelvis,14(28.6%)inthespines,3(6.1%)inthefemursand3(6.1%) in the ribs. The median follow-up was 17 months (range: 2-48 months). The median duration of ADT before RT was 5 months and the median pre-RT PSA was 0.7ng/ml. PSA response rate: 20 patients had a PSA decline 2 months after RT, and 13 of them decreased to < 0.1ng/ml (59.1%). The rate of biochemical relapse-free survival (bRFS) rates at 1-year and 2-year based on the nadir plus 2 ng/mL definition were 85.7% and 71.4%,respectively.3patientsoccurredbiochemicalfailureat2,13and24monthafter RTrespectively.TheyallreceivedthesecondlineADTandoneofthemdevelopedlung metastases after 23 months of ADT. Additionally, no acute or late grade 3 GI or GU toxicity was recorded. Conclusions Our study suggests that definitive IMRT is well tolerated and results in good PSA response and biochemical control in patient with bone oligometastatic prostate cancer. However, the long-term survival outcomes need to be further explored. Legal entity responsible for the study N/A Funding N/A Disclosure All authors have declared no conflicts of interest.

[Internal Strontium-89 Radiotherapy for Malignant Bony Metastasis].

[Strontium-89: a Desirable Therapeutic for Bone Metastases of Prostate Cancer].

To evaluate the treating effect of strontium-89 (89Sr) on prostate cancer bone metastases by bone imaging

Comparison of the Efficacy of Strontium-89 Chloride in Treating Bone Metastasis of Lung, Breast, and Prostate Cancers

89Srcl2 in the Treatment of Cancer Patients with Bone Metastasis and Pain

Preliminary Clinical Study of 89sr in Palliation in Painful Skeletal Metastases

Efects of Strontium-89 combined with Zoledronic acid for bone metastases

THE EFFICACY OF 89 SRCL2 FOR BONE METASTASES IN MALIGNANT TUMOR

Clinical Study of 89 Sr Therapy with Radiosensitization by Nicotinamide and Carbogen in Multiple Bone Metastasis of Malignant Neoplasms

Clinical Effect of 89srcl2 in the Treatment of Breast Cancer Patients with Bone Metastasis

A multicentre study on 89SrCl2 therapy in patients with painful bone metastases

Combining Strontium-89 with ~(99)Tc-MDP for treatment of:painful bone metastases of prostate cancer

Strontium-89 plus zoledronic acid versus zoledronic acid for patients with painful bone metastatic breast cancer

Experimental Study on Roles of 99Mtc-Hl91 Imaging and Carbogen Breathing in 32P-Colloid Interstitial Treatment of Malignant Tumor

Radioactivity Seeds Interstitial Brachtherapy Treating Malignant Salivary Gland Tumors

Recent progress of nuclear medicine evaluation of curative effect of 223Ra dichloride treatment on castration-resistant prostate cancer and bone metastases

Interstitial ~(125)I seed implantation in the treatment of metastatic and recurrent bone neoplasms

Clinical analysis of bone metastasis treated by 125I radioactive seeds implantation

The Use of Radiopharmaceuticals for Metastatic Bone Pain in Cancer Patients

Effect of CT guided implantation of 125Ⅰ radioactive particles in superficial malignant tumors

290P Initial Outcome of Definitive Intensity Modulated RT in Treatment of Bone Oligometastatic Prostate Cancer